Healthy subjects produce both anti-factor VIII and specific anti-idiotypic antibodies.
Open Access
- 1 October 1994
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 94 (4), 1496-1505
- https://doi.org/10.1172/jci117489
Abstract
Anti-Factor VIII (FVIII) antibodies were prepared by a combination of salt precipitation, gel filtration chromatography, and specific adsorption over insolubilized FVIII from the serum of 10 healthy subjects with normal levels of FVIII. Antibody specificity was confirmed by the capacity to recognize soluble and insolubilized FVIII and to neutralize FVIII cofactor activity in FX activation. Epitope mapping was carried out using a competition ELISA in which affinity-purified human antibodies inhibited the binding of labeled monoclonal antibodies. In most cases, a single region of the A3 domain of the FVIII light chain was recognized by the antibodies, while the reactivity toward heavy chain epitopes differed from one antibody preparation to the other. Sera or IgG fractions of the serum before immunoadsorption over insolubilized FVIII did not bind to FVIII. The IgG fraction that was not retained on the FVIII immunosorbent contained IgG that bound to the variable part of anti-FVIII mouse monoclonal antibodies and inhibited the binding of labeled FVIII; in addition, the IgG fraction inhibited the binding of affinity-purified human antibodies to FVIII, thereby strongly suggesting the presence of anti-idiotypic antibodies. These findings indicate that the presence of anti-FVIII antibodies is a more universal phenomenon than previously thought and that anti-idiotypic antibodies capable of inhibiting the binding of anti-FVIII antibodies to FVIII are produced spontaneouslyThis publication has 22 references indexed in Scilit:
- Expression and control of the natural autoreactive IgG repertoire in normal human serumEuropean Journal of Immunology, 1993
- Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals.Proceedings of the National Academy of Sciences, 1992
- Incidence of development of factor VIII and factor IX inhibitors in haemophiliacsThe Lancet, 1992
- Inhibition of human coagulation factor VIII by monoclonal antibodies. Mapping of functional epitopes with the use of recombinant factor VIII fragmentsBiochemical Journal, 1989
- Factor VIII structure and functionBlood Reviews, 1989
- Disappearance of factor VIII:C antibodies in patients with haemophilia A upon frequent administration of factor VIII in intermediate or low doseBritish Journal of Haematology, 1986
- INTRAVENOUS IgG FOR PATIENTS WITH SPONTANEOUS INHIBITOR TO FACTOR VIIIThe Lancet, 1985
- ANTI-IDIOTYPIC SUPPRESSION OF AUTOANTIBODIES TO FACTOR VIII (ANTIHAEMOPHILIC FACTOR) BY HIGH-DOSE INTRAVENOUS GAMMAGLOBULINThe Lancet, 1984
- Differentiation of thrombin- and factor Xa-related amidolytic activity in plasma by means of a synthetic thrombin inhibitorThrombosis Research, 1984
- Genetics, Expression, and Function of IdiotypesAnnual Review of Immunology, 1983